表紙
市場調査レポート

認知機能障害:世界の治験レビュー

Cognitive Impairment Global Clinical Trials Review, H1, 2014

発行 GlobalData 商品コード 306656
出版日 ページ情報 英文 106 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
認知機能障害:世界の治験レビュー Cognitive Impairment Global Clinical Trials Review, H1, 2014
出版日: 2014年06月20日 ページ情報: 英文 106 Pages
概要

当レポートでは、認知機能障害に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、G7諸国およびE7(新興7カ国)における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んで、お届けします。

目次

イントロダクション

  • 認知機能障害
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域上位5ヶ国における治験件数
    • 欧州上位5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東およびアフリカの上位5ヵ国における治験件数
    • ラテンアメリカの主要国における治験件数

G7諸国における治験件数:中枢神経系治験に対する認知機能障害治験件数比率

G7諸国における治験件数:フェーズ(相)別

G7諸国における治験件数:進捗状況別

E7(新興7カ国)における治験件数:中枢神経系に対する認知機能障害の治験件数比率

E7(新興7カ国)における治験件数:フェーズ(相)別

E7(新興7カ国)における治験件数:進捗状況別

治験件数:フェーズ(相)別

  • 進行中の治験:フェーズ別

進捗状況別の治験件数

評価項目別の治験件数

未完了の治験

一定期間に採用された被験者数

スポンサーの種類別の治験件数

有望なスポンサー

有望な薬剤

治験のプロファイル

  • 代表的企業の治験の概要
    • Pfizer Inc.
    • Novartis AG
    • Johnson & Johnson
    • Eli Lilly and Company
    • Merck & Co., Inc.
    • エーザイ
    • AbbVie Inc.
    • 武田薬品
    • Shire Plc
    • GlaxoSmithKline plc
  • 代表的な研究機関病院の治験の概要
    • U.S. Department of Veterans Affairs
    • University of Washington
    • Charite - Universitatsmedizin Berlin
    • University Hospital Basel
    • National Institute on Aging
    • Vanderbilt University
    • University of Pennsylvania
    • Emory University
    • University Hospital, Angers
    • National Institute of Mental Health

5つの代表的な治験のプロファイル

付録

図表一覧

目次
Product Code: GDHC2204CTIDB

GlobalData's clinical trial report, "Cognitive Impairment Global Clinical Trials Review, H1, 2014" provides data on the Cognitive Impairment clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cognitive Impairment. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cognitive Impairment. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Cognitive Impairment
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Cognitive Impairment to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Cognitive Impairment to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Cognitive Impairment
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Cognitive Impairment Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • Johnson & Johnson
      • Clinical Trial Overview of Johnson & Johnson
      • Eli Lilly and Company
      • Clinical Trial Overview of Eli Lilly and Company
      • Merck & Co., Inc.
      • Clinical Trial Overview of Merck & Co., Inc.
      • Eisai Co., Ltd.
      • Clinical Trial Overview of Eisai Co., Ltd.
      • AbbVie Inc.
      • Clinical Trial Overview of AbbVie Inc.
      • Takeda Pharmaceutical Company Limited
      • Clinical Trial Overview of Takeda Pharmaceutical Company Limited
      • Shire Plc
      • Clinical Trial Overview of Shire Plc
      • GlaxoSmithKline plc
      • Clinical Trial Overview of GlaxoSmithKline plc
    • Clinical Trial Overview of Top Institutes / Government
      • U.S. Department of Veterans Affairs
      • Clinical Trial Overview of U.S. Department of Veterans Affairs
      • University of Washington
      • Clinical Trial Overview of University of Washington
      • Charite - Universitatsmedizin Berlin
      • Clinical Trial Overview of Charite - Universitatsmedizin Berlin
      • University Hospital Basel
      • Clinical Trial Overview of University Hospital Basel
      • National Institute on Aging
      • Clinical Trial Overview of National Institute on Aging
      • Vanderbilt University
      • Clinical Trial Overview of Vanderbilt University
      • University of Pennsylvania
      • Clinical Trial Overview of University of Pennsylvania
      • Emory University
      • Clinical Trial Overview of Emory University
      • University Hospital, Angers
      • Clinical Trial Overview of University Hospital, Angers
      • National Institute of Mental Health
      • Clinical Trial Overview of National Institute of Mental Health
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Cognitive Impairment Therapeutics, Global, Clinical Trials by Region, 2014*
  • Cognitive Impairment Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Cognitive Impairment Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
  • Proportion of Cognitive Impairment to Central Nervous System Clinical Trials, G7 Countries (%), 2014*
  • Cognitive Impairment Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Cognitive Impairment Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Cognitive Impairment to Central Nervous System Clinical Trials, E7 Countries (%), 2014*
  • Cognitive Impairment Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Cognitive Impairment Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Cognitive Impairment Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Cognitive Impairment Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Cognitive Impairment Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Cognitive Impairment Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Cognitive Impairment Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Cognitive Impairment Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Cognitive Impairment Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by Eisai Co., Ltd., 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by Shire Plc, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by Charite - Universitatsmedizin Berlin, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital Basel, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute on Aging, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by Vanderbilt University, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pennsylvania, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by Emory University, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by University Hospital, Angers, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Mental Health, 2014*

List of Figures

  • Cognitive Impairment Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Cognitive Impairment Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Cognitive Impairment Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014*
  • Proportion of Cognitive Impairment to Central Nervous System Clinical Trials, G7 Countries (%), 2014*
  • Cognitive Impairment Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Cognitive Impairment Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Cognitive Impairment to Central Nervous System Clinical Trials, E7 Countries (%), 2014*
  • Cognitive Impairment Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Cognitive Impairment Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Cognitive Impairment Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Cognitive Impairment Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Cognitive Impairment Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Cognitive Impairment Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Cognitive Impairment Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top